Incannex Commences Screening for OSA Study
Incannex has started screening participants for its IHL-42X Phase 2 OSA trial. The company previously received FDA Fast Track designation for the drug.
View filing at SEC.gov →4 most recent filings and news items mentioning IXHL. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/IXHL/news?limit=20"
Pull IXHL filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayIncannex has started screening participants for its IHL-42X Phase 2 OSA trial. The company previously received FDA Fast Track designation for the drug.
View filing at SEC.gov →Incannex Healthcare Inc. announced the USPTO has granted a patent covering its proprietary oral therapy IHL-42X for obstructive sleep apnea. This intellectual property milestone strengthens the commercial value of the asset and supports its long-term strategic development.
View filing at SEC.gov →Incannex Healthcare received A$6.0 million in non-dilutive funding from Australia's R&D Tax Incentive Program, with an additional A$5.1 million expected later in 2026, totaling over A$11.1 million. The non-dilutive capital strengthens the company's balance sheet and provides flex
View filing at SEC.gov →Alliance Global Partners has initiated equity research coverage of Incannex Healthcare with a BUY rating and $18.00 price target, authored by analyst James Molloy. The coverage highlights the company's clinical pipeline including IHL-42X for obstructive sleep apnea and PSX-001 fo
View filing at SEC.gov →